Humulin M3 (Mixture 3) (Insulin Human (Rdna))

Humulin M3 is indicated for the management of hyperglycemia in adults with diabetes mellitus.

• Type 1 diabetes mellitus (insulin‑dependent)
• Type 2 diabetes mellitus (insulin‑requiring)
• Use when a mixed insulin profile is desired to cover both mealtime and basal needs
• May be used in combination with oral antidiabetic agents as directed by a healthcare professional
• Suitable for patients who require flexibility in injection timing
• Can be used in hospital settings for basal‑bolus insulin therapy
• May be prescribed for patients transitioning from separate regular and NPH insulin injections

• Humulin M3 delivers recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface, increasing glucose uptake, and suppressing hepatic gluconeogenesis. The mixture provides an early rapid‑acting component for post‑prandial glucose and a prolonged intermediate component for basal control.

Adverse reactions to Humulin M3 may vary in frequency and severity.

Common

• Hypoglycemia (low blood glucose)
• Injection site reactions (redness, swelling, itching)
• Lipodystrophy (localized fat changes)
• Weight gain

Serious

• Severe hypoglycemia with loss of consciousness or seizures
• Allergic reactions such as urticaria, angioedema or anaphylaxis
• Acute metabolic acidosis (rare)

When prescribing or using Humulin M3, clinicians and patients should consider several safety precautions.

• Monitor blood glucose regularly to avoid hypoglycemia
• Adjust dose during periods of illness, stress, or changes in physical activity
• Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced
• Avoid use in individuals with known hypersensitivity to human insulin or any excipients
• Consider pregnancy and lactation status; insulin requirements may change
• Review concomitant medications that affect glucose metabolism
• Educate patients on proper injection technique and site rotation

Humulin M3 can interact with other medicines that influence blood glucose or insulin action.

Avoid

• Use of other rapid‑acting insulins without adjusting total insulin dose
• Beta‑blockers that can blunt hypoglycemia warning signs
• MAO‑A inhibitors that may amplify insulin’s glucose‑lowering effect

Use with caution

• Sulfonylureas or meglitinides, which increase hypoglycemia risk
• Corticosteroids, which may raise glucose and require higher insulin doses
• Thiazide diuretics, which can affect potassium and glucose balance